PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 30663560-4 2020 Regarding antidiabetic medication, metformin, gliclazide, pioglitazone, exenatide and dapagliflozin exert a beneficial effect on Endothelial Function (EF); glimepiride and glibenclamide, dipeptidyl peptidase-4 inhibitors and liraglutide have a neutral effect, while studies examining the effect of insulin analogues, empagliflozin and canagliflozin on EF are limited. Exenatide 72-81 dipeptidyl peptidase 4 Homo sapiens 187-209 26788106-2 2015 Because GLP-1 is rapidly inactivated by the enzymatic cleavage of dipeptidyl peptidase-4 (DPP4) long-acting GLP-1 analogues, for example, exenatide and DPP4 inhibitors, for example, liraglutide, have been developed as therapeutics for type 2 diabetes mellitus (T2DM). Exenatide 138-147 dipeptidyl peptidase 4 Homo sapiens 66-88 30554037-14 2019 Finally, we show that exenatide decreased the activity of DPP-4 in TNF-alpha stimulated HRPE cells. Exenatide 22-31 dipeptidyl peptidase 4 Homo sapiens 58-63 27030119-5 2016 Clinical trials and meta-analyses have also demonstrated that patients treated with exenatide and, to a larger extent, with liraglutide are significantly more likely to achieve the composite endpoint of glycated hemoglobin <7%, no hypoglycemia and no weight gain as compared to patients exposed to other diabetes treatment, including dipeptidyl peptidase-4 inhibitors and insulin glargine. Exenatide 84-93 dipeptidyl peptidase 4 Homo sapiens 337-359 26788106-2 2015 Because GLP-1 is rapidly inactivated by the enzymatic cleavage of dipeptidyl peptidase-4 (DPP4) long-acting GLP-1 analogues, for example, exenatide and DPP4 inhibitors, for example, liraglutide, have been developed as therapeutics for type 2 diabetes mellitus (T2DM). Exenatide 138-147 dipeptidyl peptidase 4 Homo sapiens 90-94 18201204-1 2008 Exendin-4 is a dipeptidyl peptidase IV (DPP-IV)-resistant glucagon-like peptide 1 (GLP-1) mimetic and its synthetic counterpart, exenatide, is being used in the therapy of type 2 diabetes (T2DM). Exenatide 129-138 dipeptidyl peptidase 4 Homo sapiens 40-46 22382611-12 2012 Treatment drop out rate was higher in exenatide and DPP-IV inhibitors groups (in exenatide mostly for gastrointestinal side effects, in DPP-IV for inefficacy). Exenatide 38-47 dipeptidyl peptidase 4 Homo sapiens 136-142 22382611-12 2012 Treatment drop out rate was higher in exenatide and DPP-IV inhibitors groups (in exenatide mostly for gastrointestinal side effects, in DPP-IV for inefficacy). Exenatide 81-90 dipeptidyl peptidase 4 Homo sapiens 52-58 21871831-3 2011 GLP-1 secretion has also been reported to potentially affect patients with type 2 diabetes (T2DM) compared with non-diabetics and, as enzymatic inactivation by dipeptidyl peptidase-4 (DPP-4) shortens the GLP-1 half-life to a few minutes, GLP-1 receptor agonists such as exenatide twice daily (BID) and liraglutide have been developed, and have become part of the management of patients with T2DM. Exenatide 270-279 dipeptidyl peptidase 4 Homo sapiens 160-182 21871831-3 2011 GLP-1 secretion has also been reported to potentially affect patients with type 2 diabetes (T2DM) compared with non-diabetics and, as enzymatic inactivation by dipeptidyl peptidase-4 (DPP-4) shortens the GLP-1 half-life to a few minutes, GLP-1 receptor agonists such as exenatide twice daily (BID) and liraglutide have been developed, and have become part of the management of patients with T2DM. Exenatide 270-279 dipeptidyl peptidase 4 Homo sapiens 184-189 19952298-5 2009 Exenatide, a DPP-4-resistant exendin-4 GLP-1 receptor agonist, exhibits the glucoregulatory actions of GLP-1 and reduces body weight in patients with T2DM. Exenatide 0-9 dipeptidyl peptidase 4 Homo sapiens 13-18 19182763-9 2009 DPP-4 resistant incretin analogues/mimetics (e.g. exenatide, liraglutide) that have been developed by modifications/ substitutions in the polypeptide chain may be an effective alternative of the existing therapy of type-2 DM. Exenatide 50-59 dipeptidyl peptidase 4 Homo sapiens 0-5 20380648-8 2010 The glucagon-like peptide-1 (GLP-1) receptor agonists exenatide and liraglutide and the dipeptidyl peptidase-4 (DPP-4) inhibitors sitagliptin and vildagliptin effectively lower HbA1c; exenatide and liraglutide reduce weight and blood pressure and improve lipid profiles. Exenatide 184-193 dipeptidyl peptidase 4 Homo sapiens 88-110 27056542-6 2008 Injectable formulations of DPP-4-resistant GLP-1-related peptides (incretin mimetics) that are now in clinical use (exenatide) or undergoing trials (e.g. liraglutide) have been shown to reduce fasting and postprandial glucose and glycosylated hemoglobin (A1C) levels and induce weight loss. Exenatide 116-125 dipeptidyl peptidase 4 Homo sapiens 27-32 18402245-10 2008 Fortunately, many GLP-1 agonists or analogues and DPP-4 inhibitors have been found or developed, such as exendin-4, exenatide, liraglutide, CJC1131, vidaliptin and P32/98. Exenatide 105-114 dipeptidyl peptidase 4 Homo sapiens 50-55 18630617-5 2008 Exenatide is a synthetic analogue GLP-1 which is resistant to enzymatic degradation by DPP IV. Exenatide 0-9 dipeptidyl peptidase 4 Homo sapiens 87-93 17263764-9 2007 The DPP-IV resistant analogue, exenatide, has Food and Drug Administration (FDA) approval for the treatment of Type 2 diabetes and selective DPP-IV inhibitors are underdevelopment. Exenatide 31-40 dipeptidyl peptidase 4 Homo sapiens 4-10 18020966-15 2008 Another novel agent, naturally resistant to DPPIV that is given by subcutaneous injection is a synthetic peptide called exenatide, has recently been approved for treatment of T2D in the USA. Exenatide 120-129 dipeptidyl peptidase 4 Homo sapiens 44-49 17263764-9 2007 The DPP-IV resistant analogue, exenatide, has Food and Drug Administration (FDA) approval for the treatment of Type 2 diabetes and selective DPP-IV inhibitors are underdevelopment. Exenatide 31-40 dipeptidyl peptidase 4 Homo sapiens 141-147